Sort   by:  
 Page size 
UnknownAdding Celecoxib With or Without Zoledronic Acid for Hormone-Naive Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.
Not available
S-EPMC5455701 | biostudies-literature
UnknownImaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST).
Not available
S-EPMC7614664 | biostudies-literature
UnknownTiming of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial.
Not available
S-EPMC7616947 | biostudies-literature
UnknownAnalysis of Genetically Regulated Gene Expression Identifies a Prefrontal PTSD Gene, SNRNP35, Specific to Military Cohorts.
Not available
S-EPMC7359754 | biostudies-literature
UnknownLargest GWAS of PTSD (N=20 070) yields genetic overlap with schizophrenia and sex differences in heritability.
Not available
S-EPMC5696105 | biostudies-literature
UnknownTiming of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047).
Not available
S-EPMC7617161 | biostudies-literature
UnknownCelecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.
Not available
S-EPMC3398767 | biostudies-literature
UnknownAbiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Not available
S-EPMC8811484 | biostudies-literature
UnknownAbiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
Not available
S-EPMC7616864 | biostudies-literature
UnknownAddition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Not available
S-EPMC4800035 | biostudies-literature
Sort   by:  
 Page size